Yevgeny Beiderman
digital health
digital health

The company develops electro-optic device for Alzheimer’s disease (AD) early detection & deterioration follow-up, by real-time imaging of AD’s Bio-markers at the CerebroSpinal Fluid (CSF).

This is the only known non-invasive direct CSF analysis, and is Ionizing radiation free, pain free and risk free. Therefore, tests can be performed daily \ weekly, for frequent patient monitoring.

Along with AD, the system has the potential to monitor other degenerative brain diseases